

Michael D Rawlins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4444373/publications.pdf>

Version: 2024-02-01

47
papers

3,515
citations

394421
19
h-index

243625
44
g-index

50
all docs

50
docs citations

50
times ranked

3893
citing authors

#	ARTICLE	IF	CITATIONS
1	NICE comes of age. Significance, 2020, 17, 38-41.	0.4	1
2	The UK's Life Sciences Strategy: opportunities for clinical pharmacology. British Journal of Clinical Pharmacology, 2018, 84, 2175-2177.	2.4	41
3	Improving public health by improving clinical trial guidelines and their application. European Heart Journal, 2017, 38, 1632-1637.	2.2	19
4	Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review. BMJ Open, 2016, 6, e009070.	1.9	49
5	Cost, Effectiveness, and Value. JAMA - Journal of the American Medical Association, 2016, 316, 1447.	7.4	8
6	The Prevalence of Huntington's Disease. Neuroepidemiology, 2016, 46, 144-153.	2.3	244
7	A simple tragedy with a special resonance. Journal of Health Services Research and Policy, 2015, 20, 124-125.	1.7	0
8	National Institute for Clinical Excellence: NICE works. Journal of the Royal Society of Medicine, 2015, 108, 211-219.	2.0	19
9	The "Saatchi bill" will allow responsible innovation in treatment. BMJ, The, 2014, 348, g2771-g2771.	6.0	14
10	Clinical pharmacologists in pharmacoeconomics: what is their role?. Expert Review of Clinical Pharmacology, 2014, 7, 105-107.	3.1	0
11	EVIDENCE, VALUES, AND DECISION MAKING. International Journal of Technology Assessment in Health Care, 2014, 30, 233-238.	0.5	15
12	Engaging with health-care policy. Lancet, The, 2014, 383, S7-S8.	13.7	3
13	Author's reply to Poole, Conway, Bewley, Sundar, and Chalmers and Firkins. BMJ, The, 2014, 348, g3152-g3152.	6.0	0
14	Pharmacopolitics: reflections on a subspecialty of clinical pharmacology?. European Journal of Clinical Pharmacology, 2013, 69, 11-15.	1.9	12
15	NICE times: a valedictory dispatch. Lancet, The, 2013, 381, 2225-2227.	13.7	3
16	Clinical pharmacology in health care, teaching and research. British Journal of Clinical Pharmacology, 2013, 75, 1219-1220.	2.4	6
17	A Population Approach to the Rational Use of Therapeutic Interventions. Clinical Therapeutics, 2013, 35, 1634-1638.	2.5	7
18	What's happening at NICE?. Clinical Medicine, 2013, 13, 13-18.	1.9	11

#	ARTICLE	IF	CITATIONS
19	NICE: Moving Onward. New England Journal of Medicine, 2013, 369, 3-5.	27.0	24
20	Michael Rawlins: Pet hate is the Daily Mail. BMJ, The, 2013, 347, f6321-f6321.	6.0	1
21	Article Commentary: Of snarks, boojums and national drug charts. Journal of the Royal Society of Medicine, 2013, 106, 9-9.	2.0	1
22	Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1156-1160.	1.9	167
23	HTA AND VALUE - A COMMENTARY. International Journal of Technology Assessment in Health Care, 2013, 29, 374-375.	0.5	0
24	Comparative effectiveness research: a view from the other side of the pond. Journal of Comparative Effectiveness Research, 2012, 1, 293-295.	1.4	2
25	Evidence and Quality, Practicalities and Judgments: Some Experience from NICE. Healthcare Quarterly, 2012, 15, 66-69.	0.7	4
26	Reflections: NICE, Health Economics, and Outcomes Research. Value in Health, 2012, 15, 568-569.	0.3	3
27	Crossing the fourth hurdle. British Journal of Clinical Pharmacology, 2012, 73, 855-860.	2.4	15
28	The opportunity cost of cancer care: a statement from NICE. Lancet Oncology, The, 2011, 12, 931-932.	10.7	13
29	Pharmacogenetics and cost-effectiveness analysis: a two-way street. Drug Discovery Today, 2011, 16, 873-877.	6.4	9
30	Commentary: The death of clinical freedom. International Journal of Epidemiology, 2011, 40, 859-861.	1.9	3
31	Pharmacoeconomics: NICE's approach to decision-making. British Journal of Clinical Pharmacology, 2010, 70, 346-349.	2.4	126
32	Huntington's disease out of the closet?. Lancet, The, 2010, 376, 1372-1373.	13.7	63
33	The decade of NICE. Lancet, The, 2009, 374, 351-352.	13.7	22
34	Helping to provide high quality care in primary care. Ulster Medical Journal, 2009, 78, 82-3.	0.2	1
35	De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet, The, 2008, 372, 2152-2161.	13.7	271
36	De Testimonio: on the evidence for decisions about the use of therapeutic interventions. Clinical Medicine, 2008, 8, 579-588.	1.9	121

#	ARTICLE	IF	CITATIONS
37	When are randomised trials unnecessary? Picking signal from noise. BMJ: British Medical Journal, 2007, 334, 349-351.	2.3	487
38	Paying for modern cancer care—a global perspective. Lancet Oncology, The, 2007, 8, 749-751.	10.7	18
39	Pharmacopolitics and deliberative democracy. Clinical Medicine, 2005, 5, 471-475.	1.9	48
40	National Institute for Clinical Excellence and its value judgments. BMJ: British Medical Journal, 2004, 329, 224-227.	2.3	651
41	Cutting the cost of drug development?. Nature Reviews Drug Discovery, 2004, 3, 360-364.	46.4	163
42	In pursuit of quality: the National Institute for Clinical Excellence. Lancet, The, 1999, 353, 1079-1082.	13.7	148
43	New active substances authorized in the United Kingdom between 1972 and 1994. British Journal of Clinical Pharmacology, 1998, 45, 151-156.	2.4	69
44	The efficacy of locally applied aspirin and acetaminophen in postoperative pain after third molar surgery. Clinical Pharmacology and Therapeutics, 1992, 52, 292-296.	4.7	28
45	The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 1989, 9, 297-301.	7.3	578
46	Tests of the times. Nature, 1986, 323, 366-366.	27.8	0
47	Therapeutics, Evidence and Decision-Making. , 0, , .		9